China: A Changing Picture Of Protection

Last Updated: 9 April 2014
Article by Gloria Q. Wu

The third amendment to the Trademark Law, which was passed on August 30 2013 and will take effect on May 1 2014, has brought about changes to both the procedural and substantive aspects of trademark practice in China, and some of these changes may also influence the protection of pharmaceutical trademarks. Since the amended law has not yet come into effect, the cases cited here were all decided under the law before its amendment, but this article also discusses potential expected changes to similar cases in future.

Absolute grounds for refusal

According to Article 10.1 of the Trademark Law, the following signs shall not be used as trademarks: "(7) those of fraud that may easily mislead the public in the characteristics such as the quality of goods, or place of production; and (8) those detrimental to socialist morals or customs, or having other negative influences."

The following cases illustrate the examination criteria for pharmaceutical trademarks.

Case 1

Application 4882940 for the trademark VAXEM-HIB was filed by Novartis Vaccines and Diagnostics SRL for vaccines for human purposes, pharmaceutical preparations and biological preparations for medical purposes in Class 5. The rejection of the mark by the China Trademark Office (CTMO) was upheld by the Trademark Review and Adjudication Board (TRAB), and the applicant appealed to the Beijing No 1 Intermediate Court.

The court held that the 'HIB' part of the subject mark meant 'haemophilus influenzae type B'. Although the applicant claimed that the subject mark was used only in the vaccine for haemophilus influenzae type B, the designated goods of the subject mark included "Vaccines for human purposes, pharmaceutical preparations, biological preparations for medical purposes". Thus, if the mark was used on other types of vaccine for human purposes or pharmaceutical preparations, the 'HIB' part of the subject mark could cause confusion to consumers, who might consider it to be the drug name, so as to have a negative influence under Article 10.1. Thus the court upheld the TRAB's decision and rejected the mark (June 17 2011).


This case demonstrates that it is better not to include the name of a disease or other related features of the drug in a trademark because, on the one hand, that part of the mark cannot enjoy exclusive protection against use by others, and on the other, if the designated goods are broader than what is described or indicated by that part of the mark, the whole mark will be rejected.

According to Article 29 of the amended Trademark Law, during the examination process, where the CTMO considers that the contents of the application need to be explained or revised, it may ask the applicant to provide such explanation. Failure to do so has no impact on the CTMO's decision. This new article may allow an applicant to make an amendment during prosecution in a more flexible way – for example, the examiner might allow the applicant to delete the problematic part of the mark (eg, 'HIB' in the case above) or revise the description of the goods (eg, limiting the goods to "a vaccine for haemophilus influenzae type B') in order to avoid possible rejection. However, whether to allow such communication and the specific extent of acceptable amendments are at the examiner's discretion.

Case 2

Application 7398539 for the trademark ZENPEP was filed by Aptalis Pharma Limited for pharmaceutical preparations for treating gastrointestinal spasm, medicines for human purposes and pharmaceutical preparations in Class 5. The rejection of the mark by the CTMO was upheld by the TRAB and the Beijing No 1 Intermediate Court, and the applicant appealed to the Beijing Higher Court.

The court held that the subject mark as a whole was a coined word and had no specific meaning. When seeing the subject mark, the relevant public in China would not divide the mark into 'zen' and 'pep', and thus would not consider it to have the meaning of 'zen'. The TRAB and Beijing No 1 Intermediate Court both neglected the common method of reading by the relevant Chinese public and mechanically divided the subject mark into 'zen' and 'pep' in order to consider the subject mark to have a negative influence under Article 10.1, which was incorrect. Further, many other marks starting with 'zen' have been approved for registration (eg, ZENTASE, ZENNAPAX and ZENVIQUE), proving that the CTMO and the TRAB did not consider that all marks starting with 'zen' had negative influence. In order to keep the examination criteria consistent, the subject mark should also be considered not to have negative influence. Thus, the TRAB and Beijing No 1 Intermediate Court decisions were cancelled, and the subject mark was approved for registration (December 17 2012).


The examination criteria for whether a mark should be divided and examined in terms of the meaning of each part will depend on the recognition of the relevant public in China – that is, if the relevant public would usually recognise the meaning of each part of the mark, such meaning should be examined to see whether it has negative meaning. In contrast, if the relevant public would not usually divide the mark into parts and would not recognise the specific meaning of certain parts of the mark, such meaning should not be taken into consideration when examining the mark.

According to Article 11 of the Trademark Law, the following signs shall not be registered as trademarks:

  • marks that comprise only the generic names, devices or model numbers of the goods;
  • marks that indicate simply the quality, main raw materials, function, use, weight, quantity or other features of the goods; and
  • marks that lack distinctive character.

However, the signs referred to above may be registered as trademarks if they have acquired distinctiveness through use and are readily distinguishable.

Case 3

GlaxoSmithKline LLC filed Application 6883986 for the trademark below (claim colour) in Class 5 for medicines for human purposes, pharmaceutical preparations and medicines for veterinary purposes.

The TRAB upheld the CTMO's rejection of the mark andthe applicant appealed to the Beijing No 1 Intermediate Court. The court held that the subject mark was a common profile of a man, which was likely to be considered as a background picture of drug packaging and did not distinguish the source of the goods. Therefore, it was not distinctive enough to be a trademark. In addition, the evidence of use submitted by the applicant showed that the subject mark was always used together with the registered word marks 康泰克 and 新康泰克, with the subject mark covering almost half of the front of the drug packaging, so that the relevant public considered it to be the packaging decoration rather than a trademark. The court upheld the TRAB's decision and the mark was rejected (October 26 2011).


If the actual use of the mark on the drug packaging had not been considered, the mark's inherent distinctiveness would be reasonable because there was a certain degree of design (eg, the wave shape at the throat and the top of the head), and a specific colour was claimed for the mark. However, the evidence of use submitted by the applicant led the judge to pay more attention to the way in which the mark was used on the packaging (ie, as the background picture rather than as a trademark), which had a negative effect on the applicant's own argument. Imagine if the evidence of use had shown differently – for example, if it had shown that the mark was a much smaller size compared to the font of the word mark, it might have better supported the argument that the subject mark was used as a trademark. Even if the applicant had submitted no evidence of use, the argument of inherent distinctiveness would still have had a chance of being upheld.

Relative grounds for refusal

During the substantive examination of a trademark application, the examiner will search the CTMO database to determine whether an identical or similar trademark has been filed or registered in relation to the same or similar goods before the filing date of the application under examination. If a prior mark is found, the new application shall be refused. The applicant has 15 days from receipt of the notification to appeal to the TRAB.

Pharmaceutical trademarks are assessed for similarity in the same way as other marks, by comparing factors such as:

  • appearance;
  • pronunciation;
  • meaning; and
  • other aspects of such word or device or a combination thereof.

With regard to the similarity of the designated goods, the CTMO relies mainly on the Nice Classification of Goods and Services to ascertain whether the goods fall into the same subclass or subclasses, using cross-similarity notes. In contrast, the TRAB and the courts will usually adopt a more flexible and comprehensive approach to determine whether trademarks, as well as the designated goods, are similar, taking into consideration, among other things:

  • the relevant market;
  • the function of the products;
  • the main raw material used in making the products;
  • the relevant sales channels and venues; and
  • the average consumers of the products.

Case 4

Opposed mark

Opponent's cited mark








Lin Zhongxuan (individual)

Glaxo Group Limited

Filing date

September 29 2003

July 4 1987





Soap, cakes of toilet soap, medicated soap, hair lotions, facial washing milk, cosmetics, bath lotion, sunscreen preparations, anti-microbial hand lotion and talcum powder

Pharmaceutical preparations for treating and/or relieving skin disease

The CTMO dismissed Glaxo Group Limited's opposition to Lin Zhongxuan's trademark application. Glaxo appealed, but the decision was upheld by the TRAB and the Beijing No 1 Intermediate Court, and Glaxo appealed to the Beijing Higher Court.

The court held that in determining the similarity of goods, the following factors should be taken into consideration:

  • the function, purpose, manufacturer, sales channel and consumer group; and
  • whether the relevant public would believe that the goods have a connection and easily cause confusion.

The designated goods of the opposed mark (eg, medicated soap, anti-microbial hand lotion and talcum powder) belonged to the class of cleaning products or cosmetics; whereas the designated goods of the opponent's cited mark (ie, pharmaceutical preparations for treating and/or relieving skin disease) belonged to the class of pharmaceutical products. Thus, the function of the former was beauty and cleaning, while that of the latter was treating disease. Further, the manufacturing techniques and procedures differed and the sales channels were also different. Therefore, the court upheld the decisions of the TRAB and the Beijing No 1 Intermediate Court, and the opposed mark was approved for registration (March 31 2012).


Based on the content of the decision, it is hard to tell what type of evidence was submitted by Glaxo, and particularly whether any evidence supported the similarity or close connection between the relevant goods for each mark. It would be unsurprising to find market evidence that consumers with skin problems might resort to both skincare products in Class 3 and pharmaceutical products for treating skin problems in Class 5. Thus, if a consumer who has previously used some pharmaceutical products bearing Glaxo's mark to treat skin problems sees soaps and lotions with an identical mark, it is highly likely that the consumer would consider them to be from the same source (ie, Glaxo). Furthermore, today many drug stores sell not only drugs, but also cosmetics and cleaning supplies, meaning that the goods of both parties may appear in the same shops.

Both judges and examiners rely on the facts proven by the evidence submitted, rather than on their own imagination. Particularly in cases which depend on the argument of the similarity of goods which are in different classes and are generally considered different, the amount and quality of evidence supporting the likelihood of confusion are crucial.

This article first appeared in World Trademark Review magazine issue 47, published by The IP Media Group. To view the issue in full, please go to

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.